Beam Therapeutics Inc (BEAM)
22.78
-0.36
(-1.53%)
USD |
NASDAQ |
May 06, 16:00
22.78
0.00 (0.00%)
After-Hours: 20:00
Beam Therapeutics Cash from Investing (Quarterly): 98.10M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 98.10M |
| September 30, 2023 | -10.23M |
| June 30, 2023 | -41.48M |
| March 31, 2023 | 25.45M |
| December 31, 2022 | 113.44M |
| September 30, 2022 | -36.17M |
| June 30, 2022 | -1.262M |
| March 31, 2022 | -537.34M |
| December 31, 2021 | -77.50M |
| September 30, 2021 | 76.12M |
| Date | Value |
|---|---|
| June 30, 2021 | -13.14M |
| March 31, 2021 | -279.63M |
| December 31, 2020 | -81.43M |
| September 30, 2020 | 35.23M |
| June 30, 2020 | 22.87M |
| March 31, 2020 | -76.79M |
| December 31, 2019 | 16.56M |
| September 30, 2019 | 14.21M |
| June 30, 2019 | -95.08M |
| March 31, 2019 | -2.354M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-537.34M
Minimum
Mar 2022
113.44M
Maximum
Dec 2022
-44.64M
Average
-10.23M
Median
Sep 2023
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly and Co | -1.178B |
| Moderna Inc | 118.00M |
| Editas Medicine Inc | 62.84M |
| Intellia Therapeutics Inc | 45.94M |
| Perspective Therapeutics Inc | -0.089M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 135.07M |
| Cash from Financing (Quarterly) | 33.71M |
| Free Cash Flow | -182.93M |
| Free Cash Flow Per Share (Quarterly) | 1.625 |
| Free Cash Flow to Equity (Quarterly) | 131.48M |
| Free Cash Flow to Firm (Quarterly) | 131.48M |
| Free Cash Flow Yield | -10.41% |